SeaCrest Wealth Management’s Unity Biotechnology UBX Stock Holding History

SeaCrest Wealth Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,800	Closed	-$10.7K	–	674
2025 Q2	$10.7K	Hold	27,800	–	–	﹤0.01%	616
2025 Q1	$28.9K	Buy	+27,800	New	+$50.2K	﹤0.01%	651
2022 Q3	–	Sell	-2,500	Closed	-$14K	–	1457
2022 Q2	$14K	Buy	2,500 +1,500	+150%	+$12.5K	﹤0.01%	1621
2022 Q1	$11K	Hold	1,000	–	–	﹤0.01%	708
2021 Q4	$15K	Buy	+1,000	New	+$21.9K	﹤0.01%	704

Other funds holding UBX

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

AWM

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

SeaCrest Wealth Management's UBX Position: Q3 2025 in Review

SeaCrest Wealth Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 27,800 shares — an estimated $10.7K sold.

SeaCrest Wealth Management first reported a position in UBX in Q4 2021 and held it in 5 quarters. The position peaked at $28.9K in Q1 2025. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

SeaCrest Wealth Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
SeaCrest Wealth Management sold 27,800 Unity Biotechnology shares in Q3 2025, an estimated $10.7K.
SeaCrest Wealth Management first reported a position in Unity Biotechnology in Q4 2021 and held it in 5 quarters.
SeaCrest Wealth Management's Unity Biotechnology position peaked at $28.9K in Q1 2025.
6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on SeaCrest Wealth Management's 13F filing for Q3 2025, filed 13 Nov 2025.